| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 06/24/2004 | WO2004052847A2 Tricyclic steroid hormone nuclear receptor modulators |
| 06/24/2004 | WO2004052846A1 Tetrahydro-naphthalene derivatives |
| 06/24/2004 | WO2004052845A1 Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
| 06/24/2004 | WO2004052391A1 Novel use of edg receptors |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003092580B1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 06/24/2004 | WO2003057200A3 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 06/24/2004 | WO2003053966A8 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 06/24/2004 | WO2003024386A8 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/24/2004 | WO2003018044A8 New drug |
| 06/24/2004 | US20040122218 Pyrrolopyridine potassium channel openers |
| 06/24/2004 | US20040122084 7-Methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.02,4. 05,7. 09,13]heptadec-1(17)-ene-11,16-dione derivatives; antitumor, -proliferative, -carcinogenic agents; viricides;DNA polymerase inhibitors; bactericides; solubility; stability; injections |
| 06/24/2004 | US20040122078 A compound having slowly-deactivating A-type K+ channel opening activity such as N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide |
| 06/24/2004 | US20040122042 nitrogen containing heterocyclic compounds as chymase inhibitor together with ace enzyme inhibitor are effective for the treatment of hypertension and cardiac disease |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122014 Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects |
| 06/24/2004 | US20040122006 such as 7-[(2-aminophenyl)sulfanyl]-2H-1,4-benzoxazin-3(4H)-one; oxidation/reduction; deblocking/deprotectiing; cardiovascular disorders |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040121997 20-hydroxyeicosatetraenoic acid production inhibitors |
| 06/24/2004 | US20040121956 For therapy of diseases in animals and for the control of insects that are injurious or harmful to plants or animals |
| 06/24/2004 | US20040121372 Comprises receptors for advanced glycation endproduct polypeptides for use in diagnosis and treatment inflammation, infection, sepsis, autoimmune, atherosclerotic and nervous system disorders |
| 06/24/2004 | US20040121030 Extract from the pods of lupin seeds containing lupeol |
| 06/24/2004 | US20040120996 administering as a transdermal patch, containing oxybutynin to a patient a duration about 24 to 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from 0.5:1 to 5:1 to treat overactive bladder |
| 06/23/2004 | EP1431285A1 Reverse hydroxamic acid derivatives |
| 06/23/2004 | EP1431280A1 Aryl sulfamate derivatives |
| 06/23/2004 | EP1430144A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 06/23/2004 | EP1430129A2 Asip-related proteins |
| 06/23/2004 | EP1430053A1 Chemical compounds |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430045A1 Pyrane derivatives as both ace- and nep-inhibitors |
| 06/23/2004 | EP1430043A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 06/23/2004 | EP1430031A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 06/23/2004 | EP1430020A1 Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them |
| 06/23/2004 | EP1429773A1 Process for making substituted pyrazoles |
| 06/23/2004 | EP1429754A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
| 06/23/2004 | EP1429617A2 Methods for sterilizing preparations of digestive enzymes |
| 06/23/2004 | EP1429602A1 Methods for treating disorders using plant extracts |
| 06/23/2004 | EP1252157B1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 06/23/2004 | EP1251848B1 Gyrase inhibitors and uses thereof |
| 06/23/2004 | EP1066283B1 Substituted indolealkanoic acids |
| 06/23/2004 | EP1036075B1 Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties |
| 06/23/2004 | EP1024801B1 Method for regulating size and growth of vascularized normal tissue |
| 06/23/2004 | EP0983251B1 Anti-inflammatory piperazinyl-benzyl-tetrazole derivatives and intermediates thereof |
| 06/23/2004 | EP0779889B1 PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE |
| 06/23/2004 | CN1507447A Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 06/23/2004 | CN1507429A Extract from the pods of lupin seeds containing lupeol |
| 06/23/2004 | CN1506365A Prepn process of tripterygium extractive |
| 06/23/2004 | CN1506359A Coumarin amide derivative and its prepn, medicinal composition and use |
| 06/23/2004 | CN1506081A Medicine for treating prostatosis |
| 06/23/2004 | CN1506061A Cell growth regulating factor II and its prepn process |
| 06/23/2004 | CN1506057A Cell growth regulating factor Q and its prepn process |
| 06/23/2004 | CN1154655C K receptor opioid peptides |
| 06/23/2004 | CN1154502C Shengkang injection solution (for nephrosis) and preparation technology |
| 06/23/2004 | CN1154492C Medical composition containing pentosan polysulfate and its application |
| 06/23/2004 | CN1154489C Heterocyclic vinylethers against neurological disorders |
| 06/22/2004 | US6753412 Human Eag2 |
| 06/22/2004 | US6753335 Delta agonists for nervous system pain |
| 06/22/2004 | US6753332 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
| 06/22/2004 | US6753327 Neurodegenerative disorder or neuronal damage treatment; inhibitors of calpain or cathepsin cysteine proteases; antiischemic agents; reperfusion injuries |
| 06/22/2004 | US6753150 Detection of modulators of advanced glycation end product activity; obtain sample containing advanced glycation end product activity, incubate with peptide monitor adjustment in activity, adjustment in activity indicates modulator |
| 06/22/2004 | CA2176926C .alpha.v.beta.3 integrin as a predictor of endometriosis |
| 06/22/2004 | CA2104793C Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen |
| 06/17/2004 | WO2004050690A1 NOVEL χ-CONOTOXIN PEPTIDES (-I) |
| 06/17/2004 | WO2004050688A1 NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| 06/17/2004 | WO2004050630A1 The use of aryl- and heteroaryl-substituted tetrahydroisoquinolines in the treatment of chronic and neuropathic pain, migraine headaches, and urge, stress and mixed urinary incontinence |
| 06/17/2004 | WO2004050629A2 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |
| 06/17/2004 | WO2004050628A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
| 06/17/2004 | WO2004050116A1 Protease inhibitor |
| 06/17/2004 | WO2004050082A1 The novel coumarin-amide derivatives and its preparation, said drug composition and its use |
| 06/17/2004 | WO2004050075A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | WO2004050074A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | WO2004012651A3 Composition for heart disease, method to prepare same and uses thereof |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2003106660A3 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/17/2004 | WO2003106421A3 Phenylalkylamines and pyridylalkylamines with serotoninergic receptor affinity |
| 06/17/2004 | WO2003102138A3 Elongase genes and uses thereof |
| 06/17/2004 | WO2003053334A3 Compositions and methods for the diagnosis and treatment of tumor |
| 06/17/2004 | WO2003026564A9 Pharmaceutical compositions for the treatment of urinary disorders |
| 06/17/2004 | US20040116706 Therapeutic ureas |
| 06/17/2004 | US20040116697 Novel compounds |
| 06/17/2004 | US20040116669 Prostaglandin ep1 receptor |
| 06/17/2004 | US20040116652 Method for producing and using novel human defensins as biologically active proteins for treating infections and other diseases |
| 06/17/2004 | US20040116497 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 06/17/2004 | US20040116482 Potassium channel opener |
| 06/17/2004 | US20040116468 Therapeutic agent for glomerular disease |
| 06/17/2004 | US20040116459 Remedies for vesical hyperactivity |
| 06/17/2004 | US20040116458 Chemical compounds |
| 06/17/2004 | US20040116457 Agents for improving excretory potency of urinary bladder |
| 06/17/2004 | US20040116440 Useful for diagnosis, treatment of male or female sexual dysfunction |
| 06/17/2004 | US20040116431 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 06/17/2004 | US20040116424 Aryl imidazoles and related compounds as C5a receptor modulators |
| 06/17/2004 | US20040116423 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| 06/17/2004 | US20040116405 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115259 a floating tablet including as active principle alfuzosin |
| 06/17/2004 | CA2508311A1 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |